Saltikva is currently recruiting patients in its Phase 2 study in patients diagnosed with Stage 4, metastasized pancreatic cancer. Top line, interim results of the study are available. This program has been granted Orphan Drug and FastTrack designations by the US FDA. Contact us for more information on this clinical study.

Salspera is evaluating the study of Saltikva in other terminal, solid tumor cancers. These programs have completed IND-enabling studies and are slated to enter the clinical stage.

Salspera has developed multiple new constructs with different capabilities, expressing various immuno-modulating proteins applicable for a diverse set of solid tumor cancers. These programs are in IND-enabling stages. Contact us at info@salspera.com for more information on our early stage programs.